[{"orgOrder":0,"company":"Autonomous Therapeutics","sponsor":"MiNK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"MiNK-215","moa":"FAP-expressing CAF","graph1":"Oncology","graph2":"Preclinical","graph3":"Autonomous Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autonomous Therapeutics \/ MiNK Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Autonomous Therapeutics \/ MiNK Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Autonomous Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : The collaboration will leverage Autonomous’ precision encRNA technology and MiNK’s innovative iNKT cell therapies, MiNK-215, an investigational, off-the-shelf cellular immunotherapy, and agenT-797.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 10, 2024

                          Lead Product(s) : MiNK-215

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : MiNK Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank